{
  "ticker": "LLY",
  "target_date": "2025-09-17",
  "actual_date": "2025-09-17",
  "collected_at": "2025-12-08T12:17:33.714016",
  "price": {
    "open": 760.37,
    "high": 775.82,
    "low": 755.23,
    "close": 759.0153198242188,
    "volume": 3471200,
    "change_1d_pct": -0.6,
    "change_7d_pct": 2.91,
    "change_30d_pct": -0.54
  },
  "technicals": {
    "rsi_14": 64.9,
    "sma_20": 735.36,
    "sma_50": 739.08,
    "macd": 9.134,
    "macd_signal": 5.089,
    "macd_histogram": 4.045,
    "bb_upper": 773.5,
    "bb_lower": 697.21,
    "price_vs_sma20_pct": 3.22,
    "price_vs_sma50_pct": 2.7,
    "volume_ratio": 1.02
  },
  "fundamentals": {
    "market_cap": 892597501952,
    "pe_ratio": 48.784664,
    "forward_pe": 43.940643,
    "price_to_book": 37.488518,
    "price_to_sales": 15.021887,
    "profit_margin": 30.99,
    "operating_margin": 48.29,
    "roe": 96.47,
    "roa": 17.6,
    "revenue_growth": 53.9,
    "earnings_growth": 480.4,
    "debt_to_equity": 178.516,
    "current_ratio": 1.546,
    "quick_ratio": 0.724,
    "dividend_yield": 59.0,
    "fifty_two_week_high": 1111.99,
    "fifty_two_week_low": 623.78,
    "fifty_day_avg": 911.5326,
    "two_hundred_day_avg": 811.9354,
    "analyst_target": 1056.7045,
    "analyst_recommendation": "buy",
    "num_analysts": 27,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -10.46,
    "pct_from_52w_low": 59.62
  },
  "macro": {
    "spy": {
      "price": 657.36,
      "change_1d_pct": -0.12,
      "change_7d_pct": 1.36
    },
    "vix": {
      "level": 15.72,
      "signal": "NORMAL"
    },
    "treasury_10y": {
      "yield_pct": 4.08
    },
    "dollar_index": {
      "level": 96.87
    },
    "gold": {
      "price": 3681.8
    },
    "regime": "BULL_NORMAL"
  },
  "news": [
    {
      "headline": "Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, reduced A1C by an average of 2.2% in a Phase 3 trial of children and adolescents with type 2 diabetes",
      "source": "Yahoo",
      "datetime": 1758150060,
      "summary": "Eli Lilly and Company (NYSE: LLY) today announced detailed results from SURPASS-PEDS, the first Phase 3 trial to evaluate the safety and efficacy of Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, in children and adolescents (ages 10 to less than 18) with type 2 diabetes inadequately cont",
      "url": "https://finnhub.io/api/news?id=69449806ed97261fcb25ec2ac951d33364693893304e91b55cbdd34dddd1a5dc"
    },
    {
      "headline": "Sector Update: Health Care Stocks Edge Higher Late Afternoon",
      "source": "Yahoo",
      "datetime": 1758142593,
      "summary": "Health care stocks were edging up late Wednesday afternoon, with the NYSE Health Care Index up 0.2%",
      "url": "https://finnhub.io/api/news?id=5b81c93dd0d7e72ae2d8602cd25c11a3b1652c3ee98bd19ac99c9c1b3cb7a3eb"
    },
    {
      "headline": "Eli Lilly to Invest $5B in Virginia Plant for Cancer Drugs",
      "source": "Yahoo",
      "datetime": 1758142342,
      "summary": "One of the drugmaker's biggest U.S. manufacturing commitments.",
      "url": "https://finnhub.io/api/news?id=4b8e343a033f47d6a20eff2c5c05aab670e5bf2796634211aab0155fcde54426"
    },
    {
      "headline": "Weight-loss drug giants face sternest test yet",
      "source": "Yahoo",
      "datetime": 1758135780,
      "summary": "There's a challenge with high-stakes GLP-1 medication that no one in pharma can ignore.",
      "url": "https://finnhub.io/api/news?id=5c5ed78765c3ee2bbaab154c110c9a381ddbe2c045a68a6040b4484198bc16e3"
    },
    {
      "headline": "Lilly\u2019s orforglipron trumps oral semaglutide in head-to-head trial",
      "source": "Yahoo",
      "datetime": 1758131804,
      "summary": "In the head-to-head trial, Lilly\u2019s oral drug emerged on top, outperforming Novo Nordisk\u2019s semaglutide.",
      "url": "https://finnhub.io/api/news?id=bcf6b8d1857427ff35140531d4024fa7eed83e82fbd048924d776ec042a028a1"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2025-09-17",
      "description": "xslF345X05/wk-form4_1758142191.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000126238825000004/xslF345X05/wk-form4_1758142191.xml"
    },
    {
      "form": "4",
      "date": "2025-09-17",
      "description": "xslF345X05/wk-form4_1758142140.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000242/xslF345X05/wk-form4_1758142140.xml"
    },
    {
      "form": "4",
      "date": "2025-09-17",
      "description": "xslF345X05/wk-form4_1758142082.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000134082325000006/xslF345X05/wk-form4_1758142082.xml"
    },
    {
      "form": "4",
      "date": "2025-09-17",
      "description": "xslF345X05/wk-form4_1758142037.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000240/xslF345X05/wk-form4_1758142037.xml"
    },
    {
      "form": "4",
      "date": "2025-09-17",
      "description": "xslF345X05/wk-form4_1758141956.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000131021525000005/xslF345X05/wk-form4_1758141956.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}